The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma. - Tiotropium-bromide and lung mechanics

Boehringer Ingelheim Pharma GmbH & Co. KG0 个研究点目标入组 24 人开始时间: 2006年9月28日最近更新: 2012年3月19日

试验速览

暂无简介。

•History of episodic symptoms or wheezing, breathlessness, cough or chest tightness (> 12 months)
•FEV1 > 70% of predicted
•Hyperresponsive in standard histamine challenge (PC20histamine < 8 mg/ml)
•Atopic, as reflected by one or more wheal (> 3 mm) and flare responses to skin prick test (SPT) with 10 common airborne allergen extracts (Abelló, ALK Benelux)
•Non smoking or ex-smoking (for at least 12 months, < 5 pack years)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•No usage inhaled corticosteroids for 4 weeks or oral corticosteroids for 3 months prior to and during the study.
•No usage of long acting beta2-agonists 24 hours prior to a test and during the study.
•No usage of inhaled or oral medication such as antihistamines, ketotifen, sodium chromoglycate, nedocromil sodium, leukotriene receptor antagonists, theophylline, and NSAID's for at least 2 weeks prior to and during the study.
•Prohibition of use of short acting beta2-agonists or ipatropium bromide 8 hours prior to a test.
•No history of respiratory tract infection, or relevant allergen exposure during 2 weeks prior to the study.
•No known other pulmonary abnormalities or cardiovascular diseases.
•No acute illness.

发起方